Betterlife Pharma Stock Performance

BETRF Stock  USD 0.04  0  9.25%   
On a scale of 0 to 100, BetterLife Pharma holds a performance score of 2. The firm shows a Beta (market volatility) of 2.16, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BetterLife Pharma will likely underperform. Please check BetterLife Pharma's maximum drawdown and the relationship between the semi variance and day typical price , to make a quick decision on whether BetterLife Pharma's price patterns will revert.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in BetterLife Pharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BetterLife Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
  

BetterLife Pharma Relative Risk vs. Return Landscape

If you would invest  4.50  in BetterLife Pharma on October 31, 2025 and sell it today you would lose (0.87) from holding BetterLife Pharma or give up 19.33% of portfolio value over 90 days. BetterLife Pharma is currently producing 0.367% returns and takes up 12.4192% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than BetterLife, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon BetterLife Pharma is expected to generate 16.59 times more return on investment than the market. However, the company is 16.59 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

BetterLife Pharma Target Price Odds to finish over Current Price

The tendency of BetterLife OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.04 90 days 0.04 
about 73.81
Based on a normal probability distribution, the odds of BetterLife Pharma to move above the current price in 90 days from now is about 73.81 (This BetterLife Pharma probability density function shows the probability of BetterLife OTC Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the otc stock has the beta coefficient of 2.16 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, BetterLife Pharma will likely underperform. Additionally BetterLife Pharma has an alpha of 0.246, implying that it can generate a 0.25 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   BetterLife Pharma Price Density   
       Price  

Predictive Modules for BetterLife Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BetterLife Pharma. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.0412.46
Details
Intrinsic
Valuation
LowRealHigh
0.000.0312.45
Details
Naive
Forecast
LowNextHigh
0.00070.0412.46
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.030.040.04
Details

BetterLife Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. BetterLife Pharma is not an exception. The market had few large corrections towards the BetterLife Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BetterLife Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BetterLife Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.25
β
Beta against Dow Jones2.16
σ
Overall volatility
0.01
Ir
Information ratio 0.02

BetterLife Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BetterLife Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BetterLife Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
BetterLife Pharma had very high historical volatility over the last 90 days
BetterLife Pharma has some characteristics of a very speculative penny stock
BetterLife Pharma has high likelihood to experience some financial distress in the next 2 years
BetterLife Pharma has accumulated 34.56 K in total debt with debt to equity ratio (D/E) of 0.25, which may suggest the company is not taking enough advantage from borrowing. BetterLife Pharma has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BetterLife Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, BetterLife Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BetterLife Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BetterLife to invest in growth at high rates of return. When we think about BetterLife Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (12.16 M) with loss before overhead, payroll, taxes, and interest of (22.81 K).
BetterLife Pharma has accumulated about 14.41 K in cash with (11.2 M) of positive cash flow from operations.

BetterLife Pharma Fundamentals Growth

BetterLife OTC Stock prices reflect investors' perceptions of the future prospects and financial health of BetterLife Pharma, and BetterLife Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BetterLife OTC Stock performance.

About BetterLife Pharma Performance

By analyzing BetterLife Pharma's fundamental ratios, stakeholders can gain valuable insights into BetterLife Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BetterLife Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BetterLife Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada. Betterlife Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Things to note about BetterLife Pharma performance evaluation

Checking the ongoing alerts about BetterLife Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for BetterLife Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
BetterLife Pharma had very high historical volatility over the last 90 days
BetterLife Pharma has some characteristics of a very speculative penny stock
BetterLife Pharma has high likelihood to experience some financial distress in the next 2 years
BetterLife Pharma has accumulated 34.56 K in total debt with debt to equity ratio (D/E) of 0.25, which may suggest the company is not taking enough advantage from borrowing. BetterLife Pharma has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BetterLife Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, BetterLife Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BetterLife Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BetterLife to invest in growth at high rates of return. When we think about BetterLife Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (12.16 M) with loss before overhead, payroll, taxes, and interest of (22.81 K).
BetterLife Pharma has accumulated about 14.41 K in cash with (11.2 M) of positive cash flow from operations.
Evaluating BetterLife Pharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate BetterLife Pharma's otc stock performance include:
  • Analyzing BetterLife Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BetterLife Pharma's stock is overvalued or undervalued compared to its peers.
  • Examining BetterLife Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating BetterLife Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BetterLife Pharma's management team can help you assess the OTC Stock's leadership.
  • Pay attention to analyst opinions and ratings of BetterLife Pharma's otc stock. These opinions can provide insight into BetterLife Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating BetterLife Pharma's otc stock performance is not an exact science, and many factors can impact BetterLife Pharma's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for BetterLife OTC Stock analysis

When running BetterLife Pharma's price analysis, check to measure BetterLife Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BetterLife Pharma is operating at the current time. Most of BetterLife Pharma's value examination focuses on studying past and present price action to predict the probability of BetterLife Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BetterLife Pharma's price. Additionally, you may evaluate how the addition of BetterLife Pharma to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets